Makers Laboratories Ltd

Makers Laboratories has released its financial results for the quarter ending December 2024, showing a mixed performance. While the Debtors Turnover Ratio reached a five-period high, the Profit After Tax reported a notable decline, indicating challenges in profitability despite some operational strengths.

Makers Laboratories has recently seen a revision in its score following a strong performance, reaching a new 52-week high. The stock has outperformed its sector and is currently trading above key moving averages, reflecting a positive trend. Additionally, it has been added to MarketsMOJO's list, underscoring its robust market position.

Makers Laboratories has recently seen a revision in its score, reflecting its strong market performance. The stock reached a new 52-week high, outperforming its sector and achieving significant gains over the past few days. Additionally, it has been added to MarketsMOJO's list, underscoring its robust position in the pharmaceuticals industry.

Makers Laboratories has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock reached a new 52-week high and has outperformed its sector significantly, showcasing a positive trend across various moving averages and delivering impressive returns over the past year.

Makers Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 188.9 on November 27, 2024. The stock has outperformed the sector by 7.12% and has been on an upward trend for the past 2 days, with a 13.55% increase in returns. The company's strong performance and growth in the pharmaceutical industry have gained the trust of investors and analysts.

Makers Laboratories, a microcap pharmaceutical company, has reported a strong financial performance in the quarter ending September 2024. The company's operating profit and profit before tax have reached their highest in the last five quarters, indicating a positive trend. However, the high non-operating income and its sustainability should be monitored by investors.

Makers Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 184.3 on September 20, 2024. Despite high volatility, the stock has outperformed the sector by 14.5% and has shown a strong 1-year performance of 57.07%, indicating potential for growth and stability in the industry.

Makers Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high and outperforming the sector by 4.27%. Today, the stock touched an intraday high of Rs 176.5, showing a 5.37% increase. With positive indicators and a strong performance in the past year, Makers Laboratories has the potential for growth and success in the pharmaceutical industry.

Makers Laboratories, a microcap pharmaceutical company, has reached a 52-week high on August 14, 2024, with its stock trading at Rs.174.8. It has outperformed the sector by 5.3% and has shown a trend reversal, indicating positive investor sentiment. The stock is also trading above its moving averages, showcasing a bullish trend and strong performance.

Makers Laboratories, a microcap pharmaceutical company, has shown a positive performance in the quarter ending March 2024 with a score of 6 compared to -3 in the previous quarter. Net sales and operating profit have seen a significant increase, but concerns arise with a decrease in cash and an increase in debt to equity ratio. MarketsMOJO has given a 'Sell' call for the company's stock.

Makers Laboratories, a microcap pharmaceutical company, has recently reached a 52-week high of Rs. 174 on August 6, 2024. Despite a 2.08% gain and an intraday high of Rs. 174, the stock also saw a -3.86% decrease. According to MarketsMOJO, the stock call for Makers Laboratories is 'Sell', and it has underperformed the sector by -2.52% today. However, the company has shown strong performance in the past year and is trading above its moving averages. Investors should carefully consider the stock call and performance before making any investment decisions.

On August 5th, 2024, Makers Laboratories, a microcap pharmaceutical company, reached a 52-week high with a 17.92% outperformance of the sector. Despite high volatility, the stock has been on a consecutive gain for the past two days, with a 30.27% increase. It has consistently traded higher than its moving averages, showing a positive trend. MarketsMOJO has given a 'Sell' call for the stock.

Makers Laboratories, a microcap pharmaceutical company, reported a flat performance for the quarter ending March 2024. The company's efforts in streamlining operations and cutting costs led to an improved score of 0 compared to -4 in the previous quarter. Despite a 'Sell' stock call from MarketsMOJO, Makers Laboratories remains a strong player in the industry with a diverse portfolio and global presence.

Makers Laboratories, a microcap pharmaceutical company, reported flat financial results for the quarter ending December 2023 with a slight improvement in its score. However, concerns arise from the company's low cash and cash equivalents, indicating deteriorating short-term liquidity. MarketsMOJO currently has a 'Sell' call for the company's stock. Investors are advised to carefully analyze the company's financials before making any investment decisions.

Makers Laboratories, a microcap pharmaceutical company, reported a slight increase in net sales and a significant growth in net profit for the quarter ended September 2023. However, the company's operating cash flow, short-term liquidity, and dividend payouts have declined, indicating areas for improvement. Investors should carefully evaluate these factors before investing.